JP2005531516A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531516A5
JP2005531516A5 JP2003575963A JP2003575963A JP2005531516A5 JP 2005531516 A5 JP2005531516 A5 JP 2005531516A5 JP 2003575963 A JP2003575963 A JP 2003575963A JP 2003575963 A JP2003575963 A JP 2003575963A JP 2005531516 A5 JP2005531516 A5 JP 2005531516A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
prodrug
alkoxy
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003575963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/000844 external-priority patent/WO2003077910A1/en
Publication of JP2005531516A publication Critical patent/JP2005531516A/ja
Publication of JP2005531516A5 publication Critical patent/JP2005531516A5/ja
Withdrawn legal-status Critical Current

Links

JP2003575963A 2002-03-18 2003-03-06 選択的ｅｐ４受容体アゴニストによる治療方法 Withdrawn JP2005531516A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36571102P 2002-03-18 2002-03-18
PCT/IB2003/000844 WO2003077910A1 (en) 2002-03-18 2003-03-06 Methods of treatment with selective ep4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2005531516A JP2005531516A (ja) 2005-10-20
JP2005531516A5 true JP2005531516A5 (enExample) 2006-03-23

Family

ID=28042041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575963A Withdrawn JP2005531516A (ja) 2002-03-18 2003-03-06 選択的ｅｐ４受容体アゴニストによる治療方法

Country Status (12)

Country Link
US (1) US7414071B2 (enExample)
EP (1) EP1487437B1 (enExample)
JP (1) JP2005531516A (enExample)
AT (1) ATE336247T1 (enExample)
AU (1) AU2003207900A1 (enExample)
BR (1) BR0308738A (enExample)
CA (1) CA2478653A1 (enExample)
DE (1) DE60307607T2 (enExample)
ES (1) ES2268327T3 (enExample)
MX (1) MXPA04005555A (enExample)
TW (1) TW200304816A (enExample)
WO (1) WO2003077910A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
JP4582456B2 (ja) * 2003-01-21 2010-11-17 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体およびその医薬用途
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ATE550323T1 (de) * 2004-06-04 2012-04-15 Allergan Inc Piperidinyl-prostaglandinanaloga als den augeninnendruck senkende mittel
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP1841733A2 (en) 2004-11-08 2007-10-10 Allergan, Inc. Substituted pyrrolidone compounds as prostaglandin ep4 agonists
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
US7674786B2 (en) 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
WO2006121822A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
EP3176162B1 (en) 2012-07-19 2020-05-27 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
ES2635635T3 (es) 2013-03-15 2017-10-04 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
DK3083562T3 (da) 2013-12-17 2017-11-13 Lilly Co Eli Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer
US9540357B1 (en) * 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN114259992B (zh) * 2021-12-23 2023-06-27 复旦大学 正离子超分子有机框架固体材料在吸附生物毒素中的应用
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113873A (en) * 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) * 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
WO2000038667A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
AU2001290250A1 (en) * 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
IL155368A0 (en) * 2000-11-27 2003-11-23 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension

Similar Documents

Publication Publication Date Title
JP2005531516A5 (enExample)
CN100430052C (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
WO2006098918B1 (en) Substituted gamma lactams as therapeutic agents
HRP20161371T1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
JP2019094345A5 (enExample)
JP2011511840A5 (enExample)
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
JP2008513516A5 (enExample)
RU2007134380A (ru) Антибактериальные производные пиперидина
JP2006515587A5 (enExample)
JP2009524675A5 (enExample)
JP2007513915A5 (enExample)
JP2008511633A5 (enExample)
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
RU2002131639A (ru) Ингибиторы дипептидилпептидазы iv
JP2011511837A5 (enExample)
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
JP2009538897A5 (enExample)
JP2002523400A5 (enExample)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
CA2398794A1 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
JP2014530881A5 (enExample)
SI2315587T1 (en) A therapeutic composition comprising macitentan